Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-07-04
2006-07-04
Schnizer, Richard (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S233100, C536S023100, C536S023200, C536S023500, C536S023510, C536S024100, C435S320100, C435S455000, C435S456000
Reexamination Certificate
active
07071172
ABSTRACT:
The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The delivery vector comprises a segment encoding a secretory signal peptide. In embodiments of the invention, the delivery vector is an adeno-associated virus (AAV) vector. In other embodiments, the secretory signal peptide is a fibronectin secretory signal peptide (including variations and modifications, thereof). The delivery vectors of the invention may further comprise a heterologous nucleic acid sequence encoding a polypeptide of interest for transfer to a target cell, where the polypeptide of interest is operably associated with the secretory signal. Also disclosed are methods of transferring a nucleic acid of interest to a cell using the delivery vectors of the invention.
REFERENCES:
patent: 5342762 (1994-08-01), Mosher et al.
patent: 5618677 (1997-04-01), Ni et al.
patent: 6040172 (2000-03-01), Kaplitt
patent: 6180613 (2001-01-01), Kaplitt et al.
patent: 6365394 (2002-04-01), Gao et al.
patent: WO 92/15015 (1992-09-01), None
Watson (Nucl. Acids Res. 12(13): 5145-5164).
Patel et al (EMBO 6:2565-2572, 1987).
Yurchenko et al (J. Biol. Chem. 268(11): 8356-8365, 1993).
Schwarzbauer (J. Cell. Biol. 113(6): 1463-1473, 1991).
GenBank Accession No. NM—002026 (Nov. 15, 2001).
GenBank Accession No. Q91740 (Jul. 15, 1999).
DeSimone et al (Dev. Biol. 149 (2), 357-369 (1992).
Samulski et al (J. Virol. 63(9): 3822-3828, 1989).
D'Ercole et al (Progress in Growth Factor Research 6(2-4): 1995), abstract only.
During et al., “Glucagon-like peptide-1 receptor is involved in learning and neuroprotection,” Abstract,Nat. Med. (Aug. 17, 2003).
Freese et al., “Direct Gene Transfer Into Human Epileptogenic Hippocampal Tissue with an Adeno-Associated Virus Vector: Implications for a Gene Therapy Approach to Epilepsy,”Epilepsia38(7): 759-766 (1997).
Goss et al., “Herpes Simplex-Mediated Gene Transfer of Nerve Growth Factor Protects Against Peripheral Neuropathy in Streptozotocin-Induced Diabetes in the Mouse,”Diabetes51 2227-2232 (Jul. 2002).
Haberman et al., “Inducible long-term gene expression in brain with adeno-associated virus gene transfer,”Gene Therapy1604-1611 (1998).
Haberman et al., “Therapeutic Liabilities ofin VivoViral Vector Tropism: Adeno-Associated Virus Vectors, NMDAR1 Antisense, and Focal Seizure Sensitivity,”Molecular Therapy6(4) 495-500.
Haberman, et al., “Regulated Suppression of Focal Seizure Sensitivity by Adeno-Associated Virus (AAV) Vector-Dependent Galanin Secretion,” Program No. 619.10Abstract Viewer/Itinerary PlannerWashington, DC: Society for Neuroscience (2002).
Huber et al., “Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy,”PNAS98(13) 7611-7616 (2001).
Kaplitt et al., “Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain,”Nature Genetics8 148-154 (1994).
Klein et al., “NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats,”Elsevier Science B.V., Brain Research875 144-151 (2000).
Kordower et al., “Neurodegeneration Prevented by Lentiviral Vecotr Delivery of GDNF in Primate Models of Parkinson's Disease,”Science290 767-772 (Oct. 27, 2000).
Larsson et al., “Suppression of Insult-Induced Neurogenesis in Adult rat Brain by Brain-Derived Neurotrophic Factor,”Experimental Neurology177 1-8 (2002).
Luo et al., “Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model,”Science298 425-429 (Oct. 11, 2002).
Manno et al., “AAV-mediated actor IX gene transfer to skeletal muscle in patients with severe hemophilia B,”Blood101(8) 2963-2972 (Apr. 15, 2003).
McCown et al., “Differential and persistent expression patterns of CNS gene transfer by a adeno-associated virus (AAV) vector,”Elsvier Science B.V., Brain Research99-107 (1996).
Naldini et al., “Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector,”Proc. Natl. Acad. Sc.I. USA93 11382-11388 (Oct. 1996).
Xia et al., “the HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed form recombinant viral vectors,”Nature Biotechnology19 640-644 (Jul. 2001).
Haberman Rebecca P.
McCown Thomas J.
Myers Bigel Sibley & Sajovec P.A.
Schnizer Richard
The University of North Carolina at Chapel Hill
LandOfFree
Secretion signal vectors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Secretion signal vectors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Secretion signal vectors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3541215